The plan details five goals to guide the development of Sentinel, a national electronic system for medical product safety surveillance established as part of the FDA Amendments Act of 2007, over the next five years.
On Jan. 9, 2019, FDA issued the Sentinel 5-Year Strategic Plan: 2019-2023, a plan that lays out major goals for the future of the Sentinel System, a national electronic system for medical product safety surveillance established as part of the FDA Amendments Act of 2007, and FDA Catalyst, which leverages the Sentinel infrastructure and other capabilities of the system to answer a wider range of questions than can be addressed by the system data alone.
The agency states that the plan is intended to serve as a roadmap to guide the development of Sentinel over the next five years. Specifically, the plan discusses five strategic aims:
The plan will be discussed at the next Annual Sentinel Public Workshop on April 3–5, 2019 in Bethesda and Silver Spring, MD, in which FDA will share recent developments within the Sentinel Initiative, provide training on system’s tools and data infrastructure, and promote engagement and collaboration with patients, industry, and consumers.
Source: FDA
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.